Study on GD2 Positive Solid Tumors by 4SCAR-GD2
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Study ID
- NCT02992210
- Phase
- PHASE1/PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Solid Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Year - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- 4SCAR-GD2 — GENETICGD2-specific 4th Generation CART
Study Details
Patients with refractory and/or recurrent solid tumor have poor prognosis despite complex multimodel therapy and therefore, novel approaches are urgently needed. The investigators are attempt to treat these diseases using T cells genetically modified with a 4th generation lentiviral chimeric antigen receptor (4SCAR fused with an inducible apoptotic caspase 9 domain) targeting GD2 (4SCAR-GD2). The 4SCAR-GD2-modified T cells can recognize and kill tumor cells through the recognition of GD2, a surface protein expressed at high levels on many types of tumors but not on normal tissues. This study will evaluate the side effects and effective doses of 4SCAR-GD2 T cells in treating refractory and/or recurrent tumors.
Key Dates
- First listed
- Dec 14, 2016
- Start date
- Dec 31, 2026
- Status verified
- Aug 2026
- Primary completion
- Jun 30, 2028
- Completion
- Dec 31, 2029
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: effectiveness of 4SCAR-GD2 T cellsThe 4SCAR-GD2-modified T cells can recognize and kill tumor cells through the recognize of GD2 .This study will evaluate the side effects and effective doses of 4SCAR-GD2 T cells in treating refractory and recurrent solid tumors
Primary Outcome Measure
Number of patients with adverse events. [ Time Frame: 3 year ]
Central Contacts
- Lung-Ji Chang, PhD.+86 0755-86573763
Related Studies
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of RecurrenceEARLY_PHASE1 · Recruiting · Miller Children's & Women's Hospital Long Beach · Long Beach, California
- Umbilical Cord Blood Transplantation From Unrelated DonorsRecruiting · University of Rochester · Rochester, New York
- Dabrafenib and/or Trametinib Rollover StudyPHASE4 · Recruiting · Novartis Pharmaceuticals · Scottsdale, Arizona